Value of Serum MACC-1 as a New Diagnostic Biomarker in Breast Cancer Patients

Abstract

Breast cancer (BC) is the leading cause of cancer-related death among females. The current study is one of the initial studies to evaluate the diagnostic value of novel serum metastasis-associated in colon cancer-1 (MACC-1) markers in BC patients. Various other serum biomarkers have been used for the diagnosis of BC but this marker proved a good sensitivity and/or specificity. This cross-sectional study included 48 BC patients (Group-I) and 48 normal healthy controls (Group-II). Study subjects demographic, pathologic, and clinical information were recorded. Random blood samples were collected from the antecubital vein after aseptic precaution with 0.5% chlorhexidine gluconate. About 4.0 mL of venous blood was collected into a red screw-capped tube. Serum MACC-1 was assessed by a double-antibody sandwich ELISA method by using the commercially available kit in the Department of Laboratory Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. In this study, serum MACC-1 levels were significantly elevated (P<0.0001) in BC patients compared to the control group. The mean serum MACC- 1 was elevated in BC patients (55.21±14.75 pg/mL) compared with healthy controls (38.19±11.42 pg/mL) (P<0.0001). Also, the receiver operating characteristics (ROC) analysis showed an area under the curve (AUC) of 0.98, signifying a good discriminatory ability of serum MACC-1 marker for BC patients. At the cut-off value of optimal cut-off value (38.35 pg/mL), the sensitivity and the specificity of serum MACC-1 were 96.7% and 92.5%, respectively. The median age was 46.3 years in BC patients and 40.2±8.4 years in the control group (P<0.0001). Therefore, this study showed that serum MACC-1 can be a potential biomarker for the diagnosis of BC.

J. of Sci. and Tech. Res. 6(1): 169-174, 2024